|Bid||1.4400 x 1200|
|Ask||1.5100 x 1800|
|Day's Range||1.4700 - 1.5075|
|52 Week Range||1.0000 - 3.1600|
|Beta (3Y Monthly)||2.54|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The bank continues to thrive, easily pacing Buffalo-based public companies in terms of annual revenue.
BUFFALO, NY / ACCESSWIRE / May 15, 2019 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2019. Cleveland BioLabs ...
BUFFALO, NY / ACCESSWIRE / March 7, 2019 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2018. Cleveland ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you're interested in Cleveland BioLabs, Inc.Read More...
The startup company will seek to develop and commercialize drugs that are capable of prolonging human health and lifespan.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Cleveland BioLabs Inc (NASDAQ:CBLI), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...
NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BUFFALO, NY / ACCESSWIRE / November 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2018. Cleveland ...
Every investor in Cleveland BioLabs Inc (NASDAQ:CBLI) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares Read More...
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2018. Cleveland BioLabs ...
BUFFALO, NY / ACCESSWIRE / August 14, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported formation of a 50-50 joint venture, named Genome Protection, Inc. (GPI), between the company and Everon BioSciences, Inc. (Everon), a leader in understanding and targeting cellular mechanisms of aging and age-related diseases. GPI's goal is to develop and commercialize drugs for anti-aging applications capable of prolonging human health and life-span. CBLI and Everon contributed relevant IP, technologies and expertise to enable GPI to effectively execute an ambitious research and development program aimed at clinical testing of entolimod and development of new products for anti-aging and other indications associated with genome damage.
BUFFALO, NY / ACCESSWIRE / August 6, 2018 / Cleveland BioLabs, Inc. (CBLI) today reported that the company has received vendor notification of delays in analytical analyses of a formulation biocomparability study required for the Company's regulatory submissions. Because the review by the United States Food and Drug Administration (FDA) of the company's pre-Emergency Use Authorization application does not take place on strict timelines, entolimod's review status with the FDA is unaffected.
LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want access to our free research report on Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ALNY as the Company’s latest news hit the wire. On June 08, 2018, the Company presented updated positive results from its Phase-1/2 study assessing lumasiran for the treatment of Primary Hyperoxaluria Type-1 (PH1) at the OxalEurope, European Hyperoxaluria Consortium in Naples, Italy. Active-Investors.com is currently working on the research report for Cleveland BioLabs, Inc. (NASDAQ: CBLI), which also belongs to the Healthcare sector as the Company Alnylam Pharma.
In this analysis, my focus will be on developing a perspective on Cleveland BioLabs Inc’s (NASDAQ:CBLI) latest ownership structure, a less discussed, but important factor. Ownership structure has been foundRead More...